A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

Martin Filipits¹, Margaretha Rudas², Raimund Jakesz³, Peter Dubsky³, Florian Fitzal³, Christian F. Singer⁴, Otto Dietze⁵, Richard Greil⁶, Andrea Jelen⁷, Paul Sevela⁷, Christa Freibauer⁸, Volkmar Müller⁹, Fritz Jänicke¹⁰, Marcus Schmidt¹¹, Heinz Kölbl¹¹, Achim Rody¹², Manfred Kaufmann¹², Werner Schrot¹³, Hiltrud Brauch¹³, Matthias Schwab¹³, Peter Fritz¹³,¹⁴, Karsten E. Weber¹⁶, Inke S. Fedele¹⁵, Guido Hennig¹⁵, Ralf Kronenwett¹⁶, Mathias Gehrmann¹⁵, and Michael Gnant³, for the EP Investigators

Abstract

Purpose: According to current guidelines, molecular tests predicting the outcome of breast cancer patients can be used to assist in making treatment decisions after consideration of conventional markers. We developed and validated a gene expression signature predicting the likelihood of distant recurrence in patients with estrogen receptor (ER)-positive, HER2-negative breast cancer treated with adjuvant endocrine therapy.

Experimental Design: RNA levels assessed by quantitative reverse transcriptase PCR in formalin-fixed, paraffin-embedded tumor tissue were used to calculate a risk score (Endopredict, EP) consisting of eight cancer-related and three reference genes. EP was combined with nodal status and tumor size into a comprehensive risk score, EPclin. Both prespecified risk scores including cutoff values to determine a risk group for each patient (low and high) were validated independently in patients from two large randomized phase III trials [Austrian Breast and Colorectal Cancer Study Group (ABCSG)-6: n = 378, ABCSG-8: n = 1,324].

Results: In both validation cohorts, continuous EP was an independent predictor of distant recurrence in multivariate analysis (ABCSG-6: P = 0.010, ABCSG-8: P < 0.001). Combining AdjuvantOnline, quantitative ER, Ki67, and treatment with EP yielded a prognostic power significantly superior to the clinicopathologic factors alone [c-indices: 0.764 vs. 0.750, P = 0.024 (ABCSG-6) and 0.726 vs. 0.701, P = 0.003 (ABCSG-8)]. EPclin had c-indices of 0.788 and 0.732 and resulted in 10-year distant recurrence rates of 4% and 4% in EPclin low-risk and 28% and 22% in EPclin high-risk patients in ABCSG-6 (P < 0.001) and ABCSG-8 (P < 0.001), respectively.

Conclusions: The multigene EP risk score provided additional prognostic information to the risk of distant recurrence of breast cancer patients, independent from clinicopathologic parameters. The EPclin score outperformed all conventional clinicopathologic risk factors. Clin Cancer Res; 17(18); 6012–20. ©2011 AACR.

Introduction

Current guidelines for the treatment of early-stage breast cancer recommend adjuvant chemotherapy for most patients with estrogen receptor (ER)-negative or HER2-positive tumors (1, 2). In contrast, selecting chemotherapy for patients with ER-positive, HER2-negative disease is more challenging as these patients represent a wide

Authors’ Affiliations: Departments of ¹Medicine I, ²Pathology, ³Surgery, and ⁴Special Gynecology, Medical University of Vienna; ⁵Department of Pathology and Microbiology, Hanusch Hospital; ⁶Department of Gynecology, Hietzing Hospital, Vienna; Departments of ⁷Pathology and ⁸Internal Medicine III, Paracelsus Private Medical University, Salzburg; ⁹Department of Pathology, Weinviertel Hospital, Mistelbach, Austria; ¹⁰Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg; ¹¹Department of Gynecology and Obstetrics, University of Mainz, Mainz; ¹²Department of Obstetrics and Gynecology, J.W. Goethe University, Frankfurt; ¹³Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology Stuttgart and University Tubingen; ¹⁴Department of Clinical Pathology, Robert Bosch Hospital, Stuttgart; ¹⁵Siemens Healthcare Diagnostics; and ¹⁶Sividon Diagnostics, Cologne, Germany

Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/).

Note: Other EP Investigators of the Austrian Breast & Colorectal Cancer Study Group (ABCSG) and the German Tamoxifen Study Group who participated in the study are listed in the Acknowledgements.

Corresponding Author: Martin Filipits, Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria. Phone: 43-1-4277-6937; Fax: 43-1-4277-65196; E-mail: martin.filipits@meduniwien.ac.at
doi: 10.1158/1078-0432.CCR-11-0926
©2011 American Association for Cancer Research.
A Molecular Predictor of Distant Recurrence in Breast Cancer

Translational Relevance

According to current guidelines, molecular tests predicting the outcome of breast cancer patients can be used to assist in making treatment decisions after consideration of conventional markers. In this study, we developed and validated a gene expression signature predicting the likelihood of distant recurrence in patients with estrogen receptor-positive, HER2-negative breast cancer treated with adjuvant endocrine therapy only. The risk score (Endopredict, EP) provided additional prognostic information to the risk of distant recurrence of breast cancer patients, independent from clinicopathologic parameters, in particular Adjuvant!Online and Ki67 labeling index. By combining the EP risk score with nodal status and tumor size, we identified breast cancer patients with very low risk for distant recurrence who may be adequately and sufficiently treated with adjuvant endocrine therapy only. This new molecular test has a strong potential to assist in optimizing adjuvant therapy and thus might improve management of patients with early-stage breast cancer.

Materials and Methods

EP and EPclin risk scores

A detailed description of the training process of EP and EPclin risk scores including sample cohorts, selection of the final set of genes, algorithm generation, and threshold definition is shown in the Supplementary Appendix.

In brief, the final training set for the development of the EP and EPclin risk score consisted of 964 ER-positive, HER2-negative tumors from patients treated with adjuvant tamoxifen only. Because the IHC-based hormone receptor status was not available for all samples, selection was based on the ESRI/ERBB2 gene expression using prespecified cutoff levels (Supplementary Appendix, section 2.4). In a top-down approach, we developed and defined the EP score consisting of 8 cancer-related genes of interest (GOI: BIRC5, UBE2C, DHCRT, RBBP8, IL6ST, AZGP1, MGP, and STC2) and 3 normalization genes (CALM2, OA21, and RPL37A; Supplementary Tables S1 and 4).

The design and calculation of the final prespecified EP score as used for validation is described as follows: Mathematically, EP is arranged as a linear combination to predict distant recurrence (Supplementary Fig. S4). Relative expression of each GOI was assessed as delta cycle threshold (ΔCt) values based on normalization on the average of 3 reference genes (CALM2, OA21, and RPL37A):

\[
\Delta C_{t}(\text{GOI}) = 20 - C_{t}(\text{GOI}) + [C_{t}(\text{CALM2}) + C_{t}(\text{OA21}) + C_{t}(\text{RPL37A})] / 3
\]

(A)

The ΔCt values were combined into the predictive unscaled risk score \( s_{u} \).

\[
s_{u} = 0.41 \cdot \Delta C_{t}(\text{BIRC5}) - 0.35 \cdot \Delta C_{t}(\text{RBBP8}) + 0.39 \cdot \Delta C_{t}(\text{UBE2C}) - 0.31 \cdot \Delta C_{t}(\text{IL6ST}) - 0.26 \cdot \Delta C_{t}(\text{AZGP1}) + 0.39 \cdot \Delta C_{t}(\text{DHCRT}) - 0.18 \cdot \Delta C_{t}(\text{MGP}) - 0.15 \cdot \Delta C_{t}(\text{STC2}) - 2.63
\]

(B)

To avoid negative score values, we defined the final, rescaled EP risk score \( s \).

\[
s = 0, \quad \text{if } 1.5 \cdot s_{u} + 18.95 < 0
\]

\[
s = 15, \quad \text{if } 1.5 \cdot s_{u} + 18.95 > 15
\]

\[
s = 1.5 \cdot s_{u} + 18.95, \quad \text{otherwise}
\]

(C)

The EP risk score ranges from 0 to 15; higher values indicate a higher risk of recurrence.

EPclin \( (s_{\text{clin}}) \), a combined score consisting of the EP risk score and clinical parameters, was constructed from the training set:

\[
s_{\text{clin}} = 0.35 \cdot t + 0.64 \cdot n + 0.28 \cdot s
\]

(D)

where \( t \) codes the tumor size (1: ≤1 cm, 2: >1 to ≤2 cm, 3: >2 to ≤5 cm, and 4: >5 cm) and \( n \) the nodal status

spectrum of different risk profiles: women who derive little benefit from chemotherapy in addition to endocrine therapy and women with high-risk disease where chemotherapy is very appropriate. Current guidelines recommend the use of validated multigene tests for the decision whether to add chemotherapy or not after consideration of conventional markers (1). Recently, several molecular tests for prediction of breast cancer prognosis have been developed to aid clinical decision making (3–5). Some tests have been developed in heterogeneous patient cohorts (6, 7). Therefore, a clear answer about their prognostic or predictive value in ER-positive and HER2-negative patients remains elusive because all published validation results are based on cohorts that include HER2-positive patients. Moreover, none of the tests published to date have been shown to outperform a combination of hormone receptors, HER2 and Ki67 assayed by immunohistochemistry (IHC).

Here, we present the validation of Endopredict (EP), a new RNA-based multigene score predicting the likelihood of distant recurrence in patients with early-stage, ER-positive, and HER2-negative breast cancer treated with adjuvant endocrine therapy only. The EP risk score and its combination with the clinical risk factors, tumor size and nodal status (EPclin), were generated in a large training set of 964 tumor samples. The prespecified risk scores and cutoff values were then validated in 2 independent external validation cohorts of 1,702 formalin-fixed, paraffin-embedded (FFPE) samples. The patients who donated the samples had been enrolled in 2 large randomized trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG) and were treated with adjuvant endocrine therapy only. The aim of the study was to show that the EP score can predict distant recurrence in both cohorts and can significantly add information to standard clinicopathologic factors.
FFPE tissue section with a silica bead–based, fully quantitative reverse transcriptase PCR RNA extraction and gene expression analysis with ERBB2 gene amplification.

Patients and tumor samples of the validation cohorts

The present investigation is part of the ABCSG translational research program (abcsg.research). Women included in the validation sets had participated in ABCSG-6 (tamoxifen-only arm) or ABCSG-8 trial and received tamoxifen for either 5 or 2 years followed by anastrozole for 3 years. Inclusion criteria and the main clinical results of these trials were reported previously (8, 9). Breast cancer patients with ER-negative and/or HER2-positive tumors were excluded from the analyses. Baseline clinical data of the validation cohorts are given in Supplementary Table S7. No samples from the validation cohorts were used for training. The clinical characteristics according to EP risk groups of the analyzed 378 patients of ABCSG-6 and the 1,324 patients of ABCSG-8 included in this study are listed in Supplementary Table S8. Of the successfully analyzed samples, 46 (12%, ABCSG-6) and 91 (7%, ABCSG-8) patients had distant recurrences at some point in time after surgery; the mean follow-up time was 97.4 (ABCSG-6) and 72.3 (ABCSG-8) months.

ABCSG-6 was a randomized phase III trial comparing tamoxifen alone for 5 years with tamoxifen in combination with aminoglutethimide for the first 2 years of treatment in postmenopausal women. In ABCSG-8, postmenopausal breast cancer patients were randomly assigned to receive tamoxifen for either 5 or 2 years followed by anastrozole for 3 years.

All FFPE tumor blocks were collected at the time of surgery prior to adjuvant therapy and were stored at room temperature. Approval was obtained from Institutional Review Boards. Tumor sections of 4 to 10 μm were cut. One section was stained by hematoxylin/eosin to confirm the presence of invasive carcinoma, and further sections were used for molecular analyses. Pathologists from participating ABCSG centers sent a representative FFPE tumor block from each woman to the central laboratory of abcsg.research at the Medical University of Vienna. Overall, 24 centers contributed samples (see Acknowledgments).

HER2 and Ki67 were assayed by IHC and evaluated centrally in the abcsg.research laboratory at the Medical University of Vienna according to standard criteria (10, 11). For Ki67 samples, a cutoff value of 11% was used for dichotomization into low or high expression (12). In case of HER2 2+ scores, FISH analyses were used to determine ERBB2 gene amplification.

RNA extraction and gene expression analysis with quantitative reverse transcriptase PCR

Total RNA was extracted from one 5- or 10-μm whole FFPE tissue section with a silica bead–based, fully automated isolation method (Tissue Preparation System, VERSANT Tissue Preparation Reagents, Siemens Healthcare Diagnostics) as described in Supplementary Appendix (13). All samples were analyzed with quantitative one-step reverse transcriptase PCR (qRT-PCR) on an ABI PRISM 7900HT (Applied Biosystems) using SuperScript III PLATINUM One-Step Quantitative RT-PCR System with ROX (Invitrogen). All PCR assays were conducted in triplicate (for details, see Supplementary Appendix). Normalized expression of GOI, EP, and EPclin was calculated as described above (Equations A–D).
Table 1. Multivariate Cox proportional hazard models for estimating the contribution of variables to predict distant recurrence

<table>
<thead>
<tr>
<th>Cox model</th>
<th>Variable</th>
<th>ABCSG-6</th>
<th></th>
<th>ABCSG-8</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Multivariate Cox model</td>
<td>Age</td>
<td>1.00 (0.96–1.04)</td>
<td>0.864</td>
<td>1.02 (0.99–1.04)</td>
<td>0.194</td>
</tr>
<tr>
<td></td>
<td>Tumor size</td>
<td>1.09 (0.70–1.71)</td>
<td>0.704</td>
<td>1.57 (1.15–2.16)</td>
<td>0.005</td>
</tr>
<tr>
<td></td>
<td>Nodal status</td>
<td>2.47 (1.75–3.48)</td>
<td>&lt;0.001</td>
<td>2.32 (1.69–3.20)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Grade</td>
<td>0.81 (0.48–1.37)</td>
<td>0.435</td>
<td>1.09 (0.60–1.99)</td>
<td>0.770</td>
</tr>
<tr>
<td></td>
<td>ER (IHC)</td>
<td>0.90 (0.58–1.40)</td>
<td>0.650</td>
<td>0.97 (0.70–1.34)</td>
<td>0.868</td>
</tr>
<tr>
<td></td>
<td>PR (IHC)</td>
<td>0.83 (0.63–1.10)</td>
<td>0.199</td>
<td>0.94 (0.77–1.15)</td>
<td>0.559</td>
</tr>
<tr>
<td></td>
<td>Ki67</td>
<td>1.03 (1.00–1.06)</td>
<td>0.086</td>
<td>1.00 (0.98–1.02)</td>
<td>0.974</td>
</tr>
<tr>
<td></td>
<td>Treatment arm</td>
<td>–</td>
<td>–</td>
<td>0.78 (0.51–1.19)</td>
<td>0.243</td>
</tr>
<tr>
<td></td>
<td>EP score</td>
<td>1.19 (1.04–1.36)</td>
<td>0.010</td>
<td>1.26 (1.15–1.38)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Bivariate Cox model</td>
<td>Adjuvant! score</td>
<td>1.03 (1.02–1.04)</td>
<td>&lt;0.001</td>
<td>1.05 (1.04–1.07)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>EP score</td>
<td>1.19 (1.06–1.32)</td>
<td>0.002</td>
<td>1.27 (1.18–1.37)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

NOTE: The table shows 4 different Cox regression models with different sets of variables in both validation cohorts. Each model is shown in 2 columns: column "Unit HR" contains the 95% CIs for the unit HR of the respective variable whereas column "P" contains the P value for the probability of the regression coefficient to be 0. Variables/units were coded according to Supplementary Table S6 in the Supplementary Appendix.

Clinicopathologic risk classification

Adjuvant!Online (software version 8.0; www.adjuvantonline.com) was used to calculate the clinicopathologic risk based on patient’s age, tumor size, tumor grade, ER status, and number of positive lymph nodes. Patients were considered as having low clinical risk when the 10-year risk as calculated by Adjuvant!Online was below 9% (14).

Validation and statistical analyses

The 2 validation studies were conducted using pre-specified objectives, assay methods, calculation procedures of scores, and cutoff values. Sample processing, qRT-PCR analyses, and calculations of scores were conducted completely blinded to clinical and outcome data by the laboratory scientists in Cologne. The scores and risk groups for each patient were then transferred to the ABCSG for statistical analysis in Vienna. The primary endpoint of the statistical analysis was distant recurrence. Statistical analysis of the validation study as well as coding of variables used in Cox regression, c-index calculations, and associated P values is described in more detail in section 3 of the Supplementary Appendix. Recurrence rates were estimated using the Kaplan–Meier method. All reported P values are results of 2-sided tests unless stated differently. Values of P < 5% were considered statistically significant.

As primary measure of the prognostic performance, the c-index was used (The Design Library: C-index; http://lib.stat.cmu.edu/S/Harrell/Design.html; ref. 15). Its relation to the time-dependent area under the receiver operator characteristic curve is shown in Supplementary Figure S8 in Supplementary Appendix. The c-index estimate of a set of variables (e.g., the combination of the Adjuvant!Online score and the EP score) was calculated as described using 10,000 randomizations (15).

P values to assess whether the EP score contains additional information on distant recurrence with respect to a fixed set of variables X are 1-sided and based on the permutation test using 10,000 random permutations with null hypothesis "EP is not related to outcome" and the c-index as test statistic.

Statistical analyses were conducted using SPSS software, version 15.0 (SPSS Inc.) and MATLAB software, version R2009b (The MathWorks, Inc.).

Results

Validation of EP and EPclin in the ABCSG-6 and ABCSG-8 cohorts

The EP score was developed using gene expression data of 964 ER-positive, HER2-negative tumors (Supplementary Fig. S4, Supplementary Appendix, Section 2). Using the prespecified threshold for discriminating samples into low or high risk of distant metastasis, the EP risk score was independently validated in 2 large randomized phase III trials. As in the training set, all women had ER-positive, HER2-negative tumors and received adjuvant tamoxifen or tamoxifen–anastrozole treatment (Supplementary Fig. S7).

qRT-PCR was successful in 378 of 395 (99.5%) and 1,324 of 1,330 (99.5%) tumors of the 2 validation cohorts. The EP risk score as continuous predictor estimates the risk of distant recurrence in individual patients at 5 or 10 years (Fig. 1A).

The relation between the EP risk score and distant recurrence was assessed by Cox models adjusted for age,
tumor size, lymph node status, tumor grade, ER, progesterone receptor (PR), Ki67 expression (IHC), and type of adjuvant endocrine therapy. In these multivariate analyses, the EP risk score was an independent predictor of distant recurrence in ABCSG-6 and ABCSG-8 (Table 1).

Subsequently, patients were dichotomized into EP low- and EP high-risk groups according to the cutoff value prespecified in the training set.

In Kaplan–Meier analyses, we observed significant differences in distant recurrence between EP low-risk and EP high-risk patients in both trials (Fig. 2A and C). At 10 years, the distant recurrence rates for patients with EP low and EP high were 8% (3%–13%) and 22% (15%–29%) in ABCSG-6 (P < 0.001) and 6% (2%–9%) and 15% (11%–20%) in ABCSG-8 (P < 0.001), respectively.

In addition, the prespecified EPclin score was also validated in the ABCSG-6 and ABCSG-8 cohorts. EPclin is a continuous predictor of distant recurrence at 5 or 10 years (Fig. 1B). Distant recurrence rates of patients with EPclin low and EPclin high were 4% (1%–8%) and 28% (20%–36%) in ABCSG-6 (P < 0.001) and 4% (2%–5%) and 22% (15%–29%) in ABCSG-8 (P < 0.001), respectively (Fig. 2B and D).

**Performance of EP in subgroups**

In subgroup analyses, we assessed potential heterogeneities of the prognostic performance of the continuous EP risk score by Cox regression analyses adjusted for the clinical risk as calculated by Adjuvant!Online. As shown in Figure 3, a higher EP risk score was associated with a significantly increased risk of distant recurrence in all analyzed subgroups including tumor size, nodal status, grading, and Ki67 and ER expression. In addition, there was no heterogeneity among the tamoxifen-only arm of ABCSG-6 and both treatment arms of ABCSG-8.

Exploratory subgroup analyses were conducted using Kaplan–Meier analyses with dichotomized EP low- and EP high-risk groups. We found significant differences in
distant recurrence between EP low-risk and EP high-risk patients in small (T1) and large (T2/T3) tumors, in node-negative and node-positive patients, in grade 1 and 2, in ER low (<80%) and high (>80%), in Ki67 low (<11%, luminal A) tumors as well as in Adjuvant!Online low (<9%) and high (>9%) patients (Supplementary Fig. S9).

**EP score adds statistically significant information to established clinicopathologic risk factors**

To assess the contribution of different clinicopathologic and molecular variables to the prediction of distant recurrence, we calculated unbiased estimates of the c-index for several combinations of variables (Fig. 4). Combination of the established prognostic markers [nodal status, tumor size, age, grade, quantitative ER (IHC), Ki67, and treatment (ABCSG-8 only)] resulted in c-indices of 0.705 in ABCSG-6 and 0.700 in ABCSG-8. However, addition of the molecular EP score to these clinicopathologic markers resulted in a significant improvement of the prognostic power (c-indices: 0.727 in ABCSG-6 and 0.728 in ABCSG-8). Similar results were obtained when using the Adjuvant!Online score as predefined multicomponent clinicopathologic risk assessment: c-indices significantly increased from 0.749 to 0.785 in ABCSG-6 and from 0.690 to 0.733 in ABCSG-8 by addition of the molecular EP score. Because quantitative ER (IHC, within ER-positive samples) and Ki67 are not included in the Adjuvant!Online score, we examined the combination of these variables with Adjuvant!Online and assessed the additional prognostic information of EP. We could show that EP significantly added prognostic power also to these clinicopathologic variables [Adjuvant!Online, quantitative ER, Ki67, and treatment (ABCSG-8 only)] in both cohorts (0.750 vs. 0.764 in ABCSG-6 and 0.701 vs. 0.726 in ABCSG-8). Most interestingly, the EPclin score had higher c-indices than all combinations of clinicopathologic variables reported above (0.788 in ABCSG-6 and 0.732 in ABCSG-8).
Finally, in an exploratory analysis, we investigated the distant recurrence rate of patients with tumors classified discordantly between Adjuvant!Online and EPclin. We found 467 (27.4%) samples with discordant classification: Adjuvant!Online high risk and EPclin low risk \((n = 345)\) or Adjuvant!Online low risk and EPclin high risk \((n = 122)\).

Within the subgroup of discordant samples outcome follows the EPclin classification rather than the Adjuvant!Online classification \((P = 0.0496; \text{Fig. 5})\).

**Discussion**

In this study, we developed and validated a new RNA-based molecular test which predicts distant recurrence in ER-positive, HER2-negative early-stage breast cancer patients. The EP score significantly adds prognostic information to established clinicopathologic factors such as Adjuvant!Online in combination with quantitative ER expression and Ki67. This is a differentiating feature not shown by other breast cancer prognosis tests so far. Moreover, we generated and validated a combined molecular/clinicopathologic score (EPclin) which outperformed the conventional risk factors alone. EPclin might be helpful in therapeutic decision making when the use of therapy in addition to endocrine therapy is uncertain after consideration of conventional markers.

With our results, we reach level I evidence according to Simon and colleagues because our study consisted of 2 category B studies using archived samples from 2 similar but separate prospective clinical trials \((16)\).

The EP risk score has several advantages compared with currently available or published prognostic multigene assays. Identification of the candidate genes was based on 3 predefined requirements. First, we used a large discovery cohort with tumor samples of nearly 1,000 patients. Second, we analyzed a homogeneous breast cancer subgroup consisting of ER-positive, HER2-negative patients only. Finally, we exclusively included patients treated homogeneously with adjuvant tamoxifen in the training set. Using this approach, we minimized confounding effects from other tumor subtypes or anticancer drugs unrelated to the primary research question. Furthermore, we have chosen a conservative approach for algorithm
design aiming at selecting the most robust assembly of prognostic genes, which resulted in a set of 8 GOI and 3 reference genes, all measured in triplicate. The requirement of both, platform (HG-U133A arrays and qRT-PCR) and sample type (fresh frozen and FFPE) transferability, assessed in a large cohort of matched tumor samples is expected to contribute to assay robustness, an important feature when the test will be used in clinical routine. Moreover, for the performance of the test, no special preparation, storage, or shipment of tissue is necessary, and assessment of gene expression was possible in 99% of the samples. This is why the test is expected to be compatible to a standard clinical workflow of breast cancer patient care using easily available FFPE tissue.

The EP risk score has not only prognostic value independent of established clinicopathologic risk factors in each of the 2 validation studies, ABCSG-6 and ABCSG-8, but also provides significant additional prognostic information to Adjuvant! Online score, quantitative ER IHC, and Ki67 labeling index. The combination of the molecular EP risk score with the clinicopathologic risk factors nodal status and tumor size resulted in the EPclin score identifying risk groups with striking differences in the 10-year distant recurrence rates. EPclin low-risk patients had a 10-year risk of distant recurrence of 4% and had, therefore, adequately been treated with adjuvant endocrine therapy only. In contrast, for EPclin high-risk patients with a 10-year distant recurrence risk of 28% (ABCSG-6) and 22% (ABCSG-8) adjuvant endocrine therapy alone may not be sufficient and additional or other adjuvant treatment may be indicated. A limitation of our study is that the optimal adjuvant therapy in the EPclin high-risk patient population remains unknown for now and needs to be determined in well-designed prospective clinical trials. A further limitation is that the validation studies have a lower number of grade 3 tumors than what would be expected in a population of postmenopausal breast cancer. However, EP-based risk classification was of borderline significance in each of the 2 validation studies, ABCSG-6 and ABCSG-8, and this was independent of—and in addition to—clinicopathologic variables, in particular to Adjuvant! Online and Ki67 labeling index. By combining the EP risk score with clinicopathologic risk factors, we identified breast cancer patients with low risk for distant recurrence who may be adequately and sufficiently treated with adjuvant endocrine therapy only. Using this new easy-to-perform multigene tool in clinical practice has a strong potential to assist in optimizing adjuvant therapy by reducing both undertreatment and overtreatment and thus might improve management of patients with early-stage breast cancer.

Disclosure of Potential Conflicts of Interest

M. Filipits received honoraria from Speakers Bureau of Astra Zeneca, Eli Lilly, and Sividon Diagnostics GmbH and is a consultant/advisory board member of Astra Zeneca. P. Dubsky received honoraria from Speakers Bureau of Novartis and Pfizer and is a consultant/advisory board member of Novartis. C.F. Singer received honoraria from Speakers Bureau of Novartis and Roche. H. Braush received honoraria from Speakers Bureau of Astra Zeneca. M. Schwab received honoraria from Speakers Bureau of Roche Molecular Diagnostics. K.E. Weber has ownership interest (including patents) from Sividon Diagnostics GmbH. R. Krontzewitz has ownership interest (including patents) from Sividon Diagnostics GmbH. M. Gran received honoraria from Speakers Bureau of Astra Zeneca, Novartis, and Sanofi-Aventis and is a consultant/advisory board member of Amgen, Astra Zeneca, Novartis, Roche, and Sanofi-Aventis. The other authors disclosed no potential conflicts of interest.

Acknowledgments

The following investigators also participated in this study: Austria: T. Bichleiner-Hofmann, S. Taucher, U. Puschnerg, R. Bartisch, G. Sieger, C. Zielinski, S. Horvath, M. Seifert, C. Dadak, R. Obwegeser, E. Kubista, A. Esseryanis, R. Milsinger-Gehmayer, E. Hanzl, and C. Sam (Medical University of Vienna); P. Mayer, M. Moks, C. Menzel, B. Milinertisch, C. Rass, R. Reitsamer, and G. Russ (Salzburg Hospital, Salzburg); R. Haider, W. Kwasny, E. Marks, W. and Stiglbauer (Wiener Neustadt Hospital, Wiener Neustadt); R. Grill, A. Nader, and M. Stierer (Hanusch Hospital, Vienna). M. Medl, S. Redenbacher, and W. Ulrich (Herzogin, Vienna); G. Reiner (Wienviertel Hospital, Mistelbach); F. Hofbauer and M. Lang (Oberpullendorf Hospital, Oberpullendorf); M. Horvath (Gässing Hospitals Kissing); P. Kier, A. Reiner-Concin, and S. Renner (Sozialmedizinisches Zentrum Ost Hospital, Vienna); P. Balcke, G. Salem, and R. Sedivy (St. Pölten Hospital, St. Pölten); E. Nessler and W. Neunitzef (Dornbirn Hospital, Dornbirn); A. Haid, A. Lang, Z. Jasarevic, and F. Offner (Academic Teaching Hospital Feldkirch, Feldkirch). C. Gruber, F. Kugler, G. Michlmayer, S. Postbauer, R. Schildberg, and W. Segl (Sisters of Mercy Hospital, Linz); F. Fridrich, R. Greul, G. Hochreiner, G. Syre, C. Tausch, and G. Wahl (Linz Hospital, Linz); A. Chott, H. Hartleb, H. Ludwig, and H. Salzer (Wilhelminenspital, Vienna); R. Kocher, G. Leitner, F. Stangl, R. Stering, and H. Rabl (Leoben Hospital, Leoben); E. Forsthuber, J. Omann, A. Hbansia, K. Holzmueller, and H. Rogatsch (Klagenfurt Hospital, Klagenfurt); F. Feichtinger, M. Rottmann, and J. Schaller (Rudolfstiftung Hospital, Vienna); F. Burger and O. Braun (Waldviertel Hospital, Horn); G. Bayer-Tiefenbach, C. Bohm, and K. Macht (Oberwart Hospital, Oberwart); B. Gebhard and W. Rausch (Vocklabruck Hospital, Vocklabruck); R. Punzengruber and W. Ohlinger (Amstetten Hospital, Amstetten); W. Döller and E. Melbinger (Wolfsberg Hospital, Wolfsberg); C. Rass, R. Reitsamer, and G. Russ (Medical University of Vienna); M. Eichelbaum (Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and University Tübingen); T. Bachleitner-Hofmann, S. Taucher, U. Pluschnig, R. Bartsch, G. Steger, E. Asseryanis, R. Michlmayer, S. Pichler, and E. Melbinger (Henry Hospital, Stuttgart and University Tübingen); B. Gebhard and W. Rausch (Vocklabruck Hospital, Vocklabruck); R. Punzengruber and W. Ohlinger (Amstetten Hospital, Amstetten); W. Döller and E. Melbinger (Wolfsberg Hospital, Wolfsberg); and H. Reutmann, S. Naud, and G. Syr (Medical University of Vienna). The following investigators also participated in this study: Austria: T. Bichleiner-Hofmann, S. Taucher, U. Puschnerg, R. Bartisch, G. Sieger, C. Zielinski, S. Horvath, M. Seifert, C. Dadak, R. Obwegeser, E. Kubista, A. Esseryanis, R. Milsinger-Gehmayer, E. Hanzl, and C. Sam (Medical University of Vienna); P. Mayer, M. Moks, C. Menzel, B. Milinertisch, C. Rass, R. Reitsamer, and G. Russ (Salzburg Hospital, Salzburg); R. Haider, W. Kwasny, E. Marks, W. and Stiglbauer (Wiener Neustadt Hospital, Wiener Neustadt); R. Grill, A. Nader, and M. Stierer (Hanusch Hospital, Vienna). M. Medl, S. Redenbacher, and W. Ulrich (Herzogin, Vienna); G. Reiner (Wienviertel Hospital, Mistelbach); F. Hofbauer and M. Lang (Oberpullendorf Hospital, Oberpullendorf); M. Horvath (Gässing Hospitals Kissing); P. Kier, A. Reiner-Concin, and S. Renner (Sozialmedizinisches Zentrum Ost Hospital, Vienna); P. Balcke, G. Salem, and R. Sedivy (St. Pölten Hospital, St. Pölten); E. Nessler and W. Neunitzef (Dornbirn Hospital, Dornbirn); A. Haid, A. Lang, Z. Jasarevic, and F. Offner (Academic Teaching Hospital Feldkirch, Feldkirch). C. Gruber, F. Kugler, G. Michlmayer, S. Postbauer, R. Schildberg, and W. Segl (Sisters of Mercy Hospital, Linz); F. Fridrich, R. Greul, G. Hochreiner, G. Syre, C. Tausch, and G. Wahl (Linz Hospital, Linz); A. Chott, H. Hartleb, H. Ludwig, and H. Salzer (Wilhelminenspital, Vienna); R. Kocher, G. Leitner, F. Stangl, R. Stering, and H. Rabl (Leoben Hospital, Leoben); E. Forsthuber, J. Omann, A. Hbansia, K. Holzmueller, and H. Rogatsch (Klagenfurt Hospital, Klagenfurt); F. Feichtinger, M. Rottmann, and J. Schaller (Rudolfstiftung Hospital, Vienna); F. Burger and O. Braun (Waldviertel Hospital, Horn); G. Bayer-Tiefenbach, C. Bohm, and K. Macht (Oberwart Hospital, Oberwart); B. Gebhard and W. Rausch (Vocklabruck Hospital, Vocklabruck); R. Punzengruber and W. Ohlinger (Amstetten Hospital, Amstetten); W. Döller and E. Melbinger (Wolfsberg Hospital, Wolfsberg); and H. Reutmann, S. Naud, and G. Syr (Medical University of Vienna).

www.aacrjournals.org Clin Cancer Res; 17(18) September 15, 2011

References


A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

Martin Filipits, Margaretha Rudas, Raimund Jakesz, et al.

Clin Cancer Res 2011;17:6012-6020. Published OnlineFirst August 1, 2011.

Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-11-0926

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2011/08/01/1078-0432.CCR-11-0926.DC1

Cited articles
This article cites 17 articles, 8 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/17/18/6012.full.html#ref-list-1

Citing articles
This article has been cited by 34 HighWire-hosted articles. Access the articles at:
/content/17/18/6012.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.